MétaCan
Menu
Back to cohort

PS1336 DISCREPANCE OF ALLELIC BURDEN CHANGES AND CLINICAL RESPONSE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS

2019· article· en· W2950158180 on OpenAlexaff
Joon Ho Moon, H.J. Cho, Dong Won Baek, Jae‐Sook Ahn, Seo Yeon Ahn, S.H. Choi, T. Kim, Z. Zhang, S.K. Sohn, D.D.H. Kim, H.‐J. Kim

Bibliographic record

VenueHemaSphere · 2019
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer CentreUniversity of Toronto
Fundersnot available
KeywordsDecitabineAzacitidineMedicineInternal medicineMyelodysplastic syndromesInternational Prognostic Scoring SystemHypomethylating agentAlleleGastroenterologyMyeloidOncologyBone marrowGeneGeneticsDNA methylationBiology

Abstract

fetched live from OpenAlex

Background: Hypomethylating agents (HMAs) such as azacitidine (AZA) and decitabine (DEC) are used to treat higher risk myelodysplastic syndrome (HR‐MDS). However, underlying genetics and allelic burden change after HMAs needs to be clarified. Aims: This study investigated the effects of alleleic burden changes on the clinical outcomes after treatment with HMAs. Methods: This study included bone marrow samples from 64 patients (34 AZA and 30 DEC) taken at diagnosis and follow‐up after median 4 cycles. Targeted deep sequencing on a custom myeloid gene panel of 84 genes (Agilent SureSelect) was performed on trios of T‐cell, pre‐HMA, and post‐HMA samples on 64 HR‐MDS patients. Results: At diagnosis, we detected 135 mutations from 54 patients. Most frequently mutated genes were TP53 (n = 9), DNMT3A (n = 7), ASXL1 (n = 7), DDX41 (n = 7) and U2AF1 (n = 6). HMAs were administered median 4 cycles (range 1–14). At follow‐up, allelic burdens were decreased from median 13.7% (range 1.5–87.7) to 1.7% (range 0.0–49.4%), where from median 9.9% to 0.8% in AZA group ( p < 0.001) and from median 17.8% to 6.7% in DEC group (p = 0.005). CR/mCR rate were higher in patients with allelic burden reduction <2% (n = 26/43, 60%) than those without (24%, n = 5/21), but not significantly different (p = 0.765). With median follow‐up duration of 19.3 months (range 0.2–99.6 months), 2‐year overall survival (OS) rates were 54.6 ± 8.1% and 44.8 ± 11.3% in patients with and without allelic burden reduction, respectively (p = 0.907). The presence of TP53 mutations did not affect the achievement of CR/mCR (p = 0.379). However, the presence of TP53 mutations were associated with inferior OS rates: 2‐year OS rates of 56.5 ± 7.2% and 22.2 ± 13.9% (p = 0.001). In the multivariate analysis, IPSS high (HR 5.34) and the presence of TP53 mutations (HR 3.42) affected adversely on OS, while the achievement of CR/mCR (HR 0.23) and the performance of allogeneic transplantation (HR 0.33) were favorable factors for OS. Summary/Conclusion: This study showed that allelic burden is decreased after treatment with both azacitidine and decitabine in HR‐MDS patients. However, the allelic burden reduction is independent to the achievement of CR and OS. The presence of TP53 mutation remained independent prognostic factor in HR‐MDS patients treated with HMAs, even with decreased allelic burden.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.652

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.285
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueHemaSphereSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207